调强放疗联合DSOX方案化疗对晚期胃癌患者血清miRNA-17水平及预后的影响  

Effect of intensity-modulated radiotherapy combined with DSOX chemotherapy on serum miRNA-17 levels and prognosis in patients with advanced gastric cancer

作　　者：刘小军[1] 莫秀娟 高飞[1] 贾利[1] 王允[1] 代红春 易光明 韩建军[1] 贾霖[1] 钟海宇 LIU Xiaojun;MO Xiujuan;GAO Fei;JIA Li;WANG Yun;DAI Hongchun;YI Guangming;HAN Jianjun;JIA Lin;ZHONG Haiyu(Department of Oncology,Mianyang Third People's Hospital,Mianyang 621000,China;Department of Nutriology,Sichuan Mental Health Center,Mianyang 621000,China)

机构地区：[1]绵阳市第三人民医院(四川省精神卫生中心)肿瘤科,四川绵阳621000 [2]绵阳市第三人民医院(四川省精神卫生中心)营养科,四川绵阳621000

出　　处：《中国肿瘤外科杂志》2020年第1期18-22,共5页Chinese Journal of Surgical Oncology

基　　金：四川省卫生和计划生育委员会科研课题(18PJ210);绵阳市卫生计生委医学科研课题(201645)。

摘　　要：目的探究调强放疗联合DSOX方案化疗对晚期胃癌患者血清微小RNA-17(miRNA-17)水平及预后的影响。方法收集绵阳市第三人民医院确诊的晚期胃癌患者96例,采用随机数字表法将患者分为观察组与对照组,均48例。治疗前,采用实时荧光定量PCR(qPCR)检测两组患者血清miRNA-17水平,同时检测卡氏(KPS)评分。随后,两组患者均给予DSOX化疗,观察组在此基础上给予调强放疗。治疗结束后,再次检测两组患者血清miRNA-17水平及KPS评分,并评估其疗效。对患者进行24个月随访,统计随访期间的死亡人数及对应的死亡时间。比较两组的生存情况。结果两组患者治疗前KPS评分和血清miRNA-17水平差异均无统计学意义(P>0.05)。治疗结束后,与对照组相比,观察组患者血清miRNA-17水平降低[(9.58±1.76)vs.(17.11±3.54)],而KPS评分升高[(74.87±8.86)分vs.(66.36±8.02)分],差异有统计学意义;治疗有效率与疾病控制率均高于对照组(18.75%vs.4.17%、70.83%vs.47.92%),差异有统计学意义(P<0.05)。生存分析结果表明,相比于观察组,对照组患者的生存时间显著缩短(P=0.002)。相比于观察组低miRNA-17患者,观察组高miRNA-17患者的生存时间显著缩短(P=0.006);相比于对照组低miRNA-17患者,对照组高miRNA-17患者的生存时间显著缩短(P=0.008)。结论调强放疗联合DSOX方案化疗可显著降低晚期胃癌患者血清miRNA-17水平,并提高患者生存率。Objective To investigate the effect of intensity-modulated radiotherapy combined with DSOX chemotherapy on serum microRNA-17(miRNA-17)levels and prognosis in patients with advanced gastric cancer.Methods Ninety-six patients with advanced gastric cancer diagnosed in Mianyang Third People's Hospital were enrolled.The patients were divided into observation group and control group by random number table method with forty eight patients in each group.Before treatment,quantitative real-time PCR(qPCR)was used to detect miRNA-17 levels in both groups,and the karnofsky score(KPS)was also measured.Subsequently,both groups of patients were given DSOX chemotherapy,and the observation group was given intensity-modulated radiotherapy.After the end of treatment,serum miRNA-17 levels and KPS scores were measured again and the efficacy was evaluated.Patients were followed up for 24 months,and the number of deaths and the corresponding time of death during the follow-up period were counted.The overall survival between the two groups was compared.Results There was no significant difference in KPS scores and serum miRNA-17 levels between the two groups before treatment(P>0.05).After treatment,compared with the control group,the serum miRNA-17 level in the observation group was lower([9.58±1.76]vs.[17.11±3.54]),and the KPS score([74.87±8.86]vs.[66.36±8.02])increased statistically(P<0.05).The treatment efficiency(18.75%vs.4.17%)and disease control rate(70.83%vs.47.92%)were higher than the control group,the difference was statistically significant(P<0.05).Survival analysis showed that the survival time of the control group was significantly shorter than that of the observation group(P=0.002).Compared with the low miRNA-17 patients in the observation group,the survival time of patients with high miRNA-17 in the observation group was significantly shortened(P=0.006).Compared with the low miRNA-17 patients in the control group,the survival time of patients with high miRNA-17 in the control group was significantly shortened(P=0.008).Co

关 键 词：胃肿瘤 调强放疗 DSOX化疗 微RNAS 

分 类 号：R735.2[医药卫生—肿瘤]